Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7959416 | 0.92 | ALDH1A1 (0.48) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL2300942 | 0.76 | NQO2 (0.42) | ALDH1A1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL622115 | 0.75 | KDM4E (0.56) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL29550130 | 0.75 | KDM4E (0.56) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL405980 | 0.72 | F7 (0.42) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL435814 | 0.72 | KDM4E (0.38) | ALDH1A1MEN1RAB9AKMT2ALMNA | |
| SCHEMBL2306818 | 0.72 | SCN10A (0.36) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL3384607 | 0.72 | ALDH1A1 (0.47) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL315256 | 0.72 | NCF1 (0.51) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL2894578 | 0.70 | EGFR (0.53) | ALDH1A1MEN1POLBRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | claimed |
| EP-4100410-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| CN-115362156-A | Muscarinic receptor 4 antagonists and methods of use | 纽罗克里生物科学有限公司 | 2022-11-18 | — | — | CN | claimed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | claimed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| EP-4100410-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115362156-A | Muscarinic receptor 4 antagonists and methods of use | 纽罗克里生物科学有限公司 | 2022-11-18 | — | — | CN | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20030212116-A1 | Heterocyclic imino compounds and fungicides and insecticides for agricultural and horitcultural use | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1243580-A1 | HETEROCYCLIC IMINO COMPOUNDS AND FUNGICIDES AND INSECTICIDES FOR AGRICULTURAL AND HORTICULTURAL USE | Nissan Chemical Industries, Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212116-A1 | Heterocyclic imino compounds and fungicides and insecticides for agricultural and horitcultural use | DDT, CBR3, CYP1B1 | ALDH1A1 1119/4885MEN1 762/4885POLB 3693/4885 |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | ALDH1A1 1378/4885MEN1 1049/4885POLB 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.